Colorectal cancer (CRC), also known as bowel cancer and colon cancer, is the development of cancer from the colon or rectum.

Globally, colorectal cancer is the third most common type of cancer in both men and women making up about 10% of all cases. Currently, there is a significant focus on development of drugs for the treatment of CRC.


Signs and symptoms of colorectal cancer include blood in the stool, a change in bowel movements, weight loss, and feeling tired all the time. It typically starts as a benign tumor, often in the form of a polyp, which over time becomes cancerous.

Colorectal clinical trials around the world

A total of 5,412 studies on Colorectal Cancer have been recorded around the world, with most trials being in Europe(1,823), North America (2,284), East Asia (893) and Pacific regions (135). (


Currently ongoing studies of colorectal cancer around the world are 1,610, particularly in North America (671), Europe (593), East Asia (364) and Pacific region (43).

OGD (USFDA) requires clinical trials on colorectal cancer drugs

Even for generic drug products, like

  • Capecitabine
  • Tipiracil Hcl, Trifluridine
  • Regorafenib

used in the CRC treatment, OGD requires a clinical trial to be conducted.

Thus, applicants intending to submit for marketing approval of these drug products are required to conduct a clinical trial in CRC patients.

With generic drugs also requiring clinical trials in CRC patients (along with so many companies going for such clinical trials), there is a significant need to identify great sites and investigators, who can provide good quality data with faster recruitment.

Colorectal Cancer Phase 2-3 Clinical Trial Feasibility

In a recently concluded clinical trial feasibility in Colorectal cancer patients on Credevo, preliminary recruitment rate was assessed in Canada and Lithuania.

The study required

– Patient with non-resectable metastatic colorectal cancer with histological or cytological documentation of adenocarcinoma of the colon or rectum
– Patient in third line or fourth line treatment for metastatic colorectal cancer

Several investigators participated in this feasibility. Here are the salient results from the assessment.

1. Canadian investigators were more responsive than those in Lithuania.
2.Average recruitment rate, reported by Canadian investigators, was 3.5 patients per site per month.
3. Highest recruitment rate reported was 5 patients per site per month.

Reasons to engage investigators / sites for CRC clinical trials in Canada

There are several.

  1. Canada has sites with both private as well as public ownership, allowing you to take benefits of both sides.
  2. Canadian investigators are definitely very qualified, experienced and, most importantly, quite motivated to engage in clinical research.
  3. Feasibility of any good clinical trial can be conducted quickly with active participation from site staff and investigators.
  4. Recruitment rate of 3.5 – 5 patients per month is possible for CRC trials, making it one of the most favorable prospective rates.
  5. Canadian regulatory process is quite smooth, well defined and quite predictable. This makes a lot easier to define projections for approvals and related timelines. Click here for details on Canadian regulatory process
  6. Regulatory approvals process is parallel for regulatory authority and ethics committee, saving some significant time.
  7. A quite convenient regulatory approval time of 30 days.
  8. Easy regulations for import of study medications.
  9. Easy study start up and management

How to Connect with Canadian Investigators for Your Colorectal Cancer Trials?

It is very helpful to engage investigators and sites when you have a preliminary design ready for your clinical trial.

Conducting feasibility with investigators and sites at this stage helps you to get information about their availability, thoughts on the study design, possible recruitment rate, besides other details such as their experience, infrastructure, potential and cost.

With Credevo, it’s quite easy to conduct feasibility with investigators in Canada. Here are few easy steps to proceed.

  1. Just sign up as a trial manager , if you’ve not already.
  2. Post your requirement with preliminary information, therapeutic segments and country (including Canada, off course)
  3. Get responses from Canadian investigators, as well as investigators from other regions
  4. Start contacting these investigators and explore more.
  5. Perform quick assessment of preliminary recruitment rates, responsiveness and possible number of sites that you can connect with

Further detailed exploration with these investigators can help assess the costs and other important considerations as well.

If there are any questions or thoughts about this, contact Credevo team here.



Comments are closed.